Complexes including a solid support and a material with a matrix structure containing domains complexing rare earth or strategic metals, preparation process thereof and use thereof for extracting or separating the rare earth or strategic metals in an aqueous or organic medium.

The present disclosure provides a phosphorus-containing compound represented by Formula (1), a resin composition comprising the phosphorus-containing compound, and an article made from the resin composition. The phosphorus-containing compound can achieve halogen-free flame retardancy while satisfying the requirements of excellent dielectricity, high copper foil peeling strength, high glass transition temperature, low percent thermal expansion and excellent heat resistance after moisture absorption. The resin composition comprises the following components or a prepolymer thereof: (A) 100 parts by weight of an unsaturated C?C double bond-containing polyphenylene ether resin; and (B) 15 parts by weight to 90 parts by weight of the phosphorus-containing compound represented by Formula (1); wherein the prepolymer is obtained from a mixture through prepolymerization, and the mixture comprises at least the component (A) and the component (B).

##STR00001##

The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. The methods generally comprise administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that is designed to be substantially active in the gastrointestinal (GI) tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions therein. More particularly, the method comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that inhibits NHE-3, -2 and/or -8 mediated antiport of sodium and/or hydrogen ions in the GI tract and is designed to be substantially impermeable to the layer of epithelial cells, or more specifically the epithelium of the GI tract. As a result of the compound being substantially impermeable, it is not absorbed and is thus essentially systemically non-bioavailable, so as to limit the exposure of other internal organs (e.g., liver, heart, brain, etc.) thereto. The present disclosure is still further directed to a method wherein a mammal is administered such a compound with a fluid-absorbing polymer, such that the combination acts as described above and further provides the ability to sequester fluid and/or salt present in the GI tract.

Provided is a resin composition having excellent flame retardance, molding processability, and post-heat aging flame retardance. A flame-retardant resin composition contains: (A) a polyphenylene ether; (B) at least one thermoplastic resin selected from the group consisting of (B-1) a polystyrene resin, (B-2) a polyamide resin, (B-3) a polypropylene resin, and (B-4) a polyphenylene sulfide resin; and (C) a flame retardant. The (A) component has a content of less than 50 mass % when the flame-retardant resin composition minus ash content is taken to be 100 mass %. The flame-retardant resin composition has a flame retardance level of V-0 as measured by a UL 94 vertical burning test. A molded article formed from the flame-retardant resin composition exhibits a rate of change of chloroform-insoluble content of no greater than 15 mass % before and after being subjected to aging in which the molded article is left for 1,000 hours at 150 C. in an atmospheric environment.

Methods for the synthesis and use of functionalized, substituted naphthalenes are described. The functionalized, substituted naphthalenes display useful properties including liquid crystals and fluorescence properties, such as solvatochromatic fluorescence, with high quantum yields, Stoke's shift, and show emission maxima that are significantly red-shifted.

In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein is versatile polyene cyclization strategy that exploits conjugated -ionyl derivatives. Photomediated disruption of the extended -system within these chromophores unveils a contra-thermodynamic polyene that engages in a Heck-type cyclization to afford [4.4.1]-propellanes. The connectivity of overbred polycycles generated from this process is controlled by the position of the requisite C-Halide bond. Thus, compared to conventional biomimetic polyene cyclization, this approach allows for complete control of regiochemistry and facilitates incorporation of both electron-rich and electron-deficient (hetero)aryl groups. This strategy was successfully applied to the total synthesis of abietanes such as, for example, taxodione and salviasperanol, two isomeric abietane-type diterpenes that previously could not be prepared along the same synthetic pathway.

The present invention relates to transition-metal-free process for the synthesis of tertiary arylamines comprises coupling reaction between arynes and N,N-dimethyl aniline compounds in presence of 18-crown-6, KF and THF.

Complexes including a solid support and a material with a matrix structure containing domains complexing rare earth or strategic metals, preparation process thereof and use thereof for extracting or separating the rare earth or strategic metals in an aqueous or organic medium.

Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are triphenyl methane analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, inflammatory, degenerative and vascular diseases, including various ocular diseases, and parasitic infections. Representative triphenyl methane analogs include triphenyl methane analogues of various dyes, hormones, sugars, peptides, oligonucleotides, amino acids, nucleotides, nucleosides, and polyols. The compounds are believed to function by inhibiting tNOX expression, the effects of ROS, and/or the production of HIF2. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases.

Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a modified polynucleic acid molecule and a polymer. Also described herein include methods for treating a cancer which utilize a composition or a pharmaceutical formulation comprising a binding moiety conjugated to a polynucleic acid molecule and a polymer.